Nature Communications (Jun 2024)

The maternal drug exposure birth cohort (DEBC) in China

  • Lu Li,
  • Ke Wang,
  • Meixian Wang,
  • Jing Tao,
  • Xiaohong Li,
  • Zhen Liu,
  • Nana Li,
  • Xiaoxia Qiu,
  • Hongwei Wei,
  • Yuan Lin,
  • Yuan He,
  • Ying Deng,
  • Hong Kang,
  • Yuting Li,
  • Ping Yu,
  • Yanping Wang,
  • Jun Zhu,
  • Hanmin Liu

DOI
https://doi.org/10.1038/s41467-024-49623-0
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Drug exposure during pregnancy lacks global fetal safety data. The maternal drug exposure birth cohort (DEBC) study, a prospective longitudinal investigation, aims to explore the correlation of maternal drug exposure during pregnancy with pregnancy outcomes, and establish a human biospecimen biobank. Here we describe the process of establishing DEBC and show that the drug exposure rate in the first trimester of pregnant women in DEBC (n = 112,986) is 30.70%. Among the drugs used, dydrogesterone and progesterone have the highest exposure rates, which are 11.97% and 10.82%, respectively. The overall incidence of adverse pregnancy outcomes is 13.49%. Dydrogesterone exposure during the first trimester is correlated with higher incidences of stillbirth, preterm birth, low birth weight, and birth defects, along with a lower incidence of miscarriage/abortion. Due to the limitations of this cohort study, causative conclusions cannot be drawn. Further follow-up and in-depth data analysis are planned for future studies.